Webinar Date/Time: Tuesday, January 17th, 2023 at 9 am CT, 10 am ET, 3 pm BST, 4 pm CET
Configurable RTSM systems present new opportunities to accelerate adoption of clinical trial platforms, while lowering the total cost of ownership. Reduce build times, gain inventory oversight, and implement mid-study changes for the simplest to the most complex studies without the need for programming or coding, which eliminates the need for prolonged user acceptance testing.
Register Free: https://www.pharmexec.com/pe/rts_system
Event Overview:
Configurable RTSM systems present new opportunities to accelerate adoption of clinical trial platforms, while lowering the total cost of ownership. As the industry continues to move away from cumbersome custom solutions, new questions arise about how to standardize approaches to RTSM ownership, manage platform adoption, conduct site and sponsor training, perform cross-study analytics and reporting, and achieve economies of scale.
Key Learning Objectives:
Who Should Attend:
Speakers
Asher Nathan
CEO, Director
NeoTX
Asher Nathan has extensive experience in diverse roles within the industry, including serving as founder, entrepreneur and investor, and has authored over 25 patents in the field of biotechnology. Before NeoTX, he founded IntelliGene and EvoRx, two biotech companies formed around technologies he invented. EvoRx was established together with Nobel Prize Winners Arthur Kornberg and Roger Kornberg. Asher was also a Managing Director at Paramount Biocapital, a drug development and healthcare investment firm that created over 40 start-up companies, before he co-founded Zoticon Bioventures, where he served as Managing Director.
Dror Graiver
Clinical Trial Manager
NeoTX
Dror is a Clinical Trial Manager at NeoTX Therapeutics. Dror holds a B.Sc. of Biology from Ben-Gurion University and a M.Sc. in Medical Sciences from Tel-Aviv University. Dror majored in drug development and implementation. In addition to working as a Clinical Trial Manager, Dror has spent time as a CRA at Karyopharm and PPD, respectively. Dror has held responsibility for the management of clinical databases, and has managed, supervised and supported multiple international clinical trials in several therapeutic fields (ie, oncology, neurology, infectious diseases, etc.).
Ryan Kennedy
Global VP, Product Strategy, Experience, and Enablement
Oracle
Ryan Kennedy is the Global VP of Product Strategy, Experience, and Enablement for Oracle Health and AI. Ryan has 22 years of clinical research experience, with roles ranging from direct site and patient management at University of Pittsburgh’s Cancer Center to working in the field of eCOA and eClinical technology development. He has a bachelor’s in Philosophy and Neuroscience from Allegheny College and a MBA from the Katz School of Business, University of Pittsburgh.
Sean Roy
Senior Consulting Practice Director
Oracle
Sean Roy is the Senior Director of North America Services for Oracle’s Health Sciences Global Business Unit. Sean has 10 years of IRT/RTSM domain expertise and 14+ years in the services delivery of clinical trial software. Sean holds a BS in Management from Bentley University, a MS in Leadership from Northeastern University, and a Ph.D. in Organizational Leadership from Indiana Wesleyan University.
Register Free: https://www.pharmexec.com/pe/rts_system
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.